NCT06807502Recruiting
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 93 (estimated)
- First submitted
- 14 Jan 2025
- Start date
- 24 Feb 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- ScreenCell
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06807502
What you commit to
- Study type: Interventional
- Planned participants: 93
- From 24 Feb 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up.
- For healthy volunteers:
- History of cancer
Age
- Age less than 18 years old
Other
- For all participants:
- Male
- Refusal to participate or withdrawal of consent
- Pregnant and/or breastfeeding women
- Detection of CTC (positive profile) during screening
Who the study is looking for
- For all participants :
- Female with age greater than or equal to 18 years
- For participants with metastatic breast cancer:
- \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion.
- For participants with non-metastatic invasive breast cancer:
- \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment)
- For healthy volunteers:
- Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion
- Participant with no history of cancer
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CMC Ambroise Paré Hartmann Coordinator of this site? Confirm its status | Neuilly-sur-Seine | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.